Cue Biopharma, Inc. (CUE) Stock Research
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Latest price: 18.6 · Sector: Healthcare
Recent Insider Transactions
| Insider | Type | Date | Value |
|---|---|---|---|
| Meluzio Michael Vincent | sell | 2026-10-12 | 32089.2 |
| Ray Sumita | sell | 2026-10-12 | 51724.2 |
| Lin Shao-Lee | sell | 2026-10-12 | 30490.35 |
| Lin Shao-Lee | sell | 2026-10-12 | 275000 |
| Meluzio Michael Vincent | sell | 2026-08-13 | 44613.03 |
| Meluzio Michael Vincent | sell | 2026-08-13 | 124617.1 |
| Meluzio Michael Vincent | sell | 2026-08-13 | 93.39 |
| Ray Sumita | sell | 2026-08-13 | 69988.71 |
| Ray Sumita | sell | 2026-08-13 | 195514.7 |
| Ray Sumita | sell | 2026-08-13 | 124.52 |